Karyopharm Therapeutics (KPTI) Income Statement
Karyopharm Therapeutics Income Statement
Last quarter (Q2 2026), Karyopharm Therapeutics's total revenue was $33.43M, a decrease of 11.86% from the same quarter last year. In Q2, Karyopharm Therapeutics's net income was $-67.02M. See Karyopharm Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 146.07M | $ 145.24M | $ 146.03M | $ 157.07M | $ 209.82M | |
| $ 140.12M | $ 139.23M | $ 141.09M | $ 151.86M | $ 206.42M | |
| $ 230.82M | $ 258.67M | $ 270.63M | $ 294.06M | $ 304.69M | |
| Depreciation and Amortization | $ 296.00K | $ 340.00K | $ 530.00K | $ 621.00K | $ 789.00K |
| $ -149.85M | $ -38.60M | $ -118.42M | $ -139.31M | $ -96.98M | |
| $ -90.71M | $ -119.44M | $ -129.54M | $ -142.20M | $ -98.27M | |
| $ -105.29M | $ 43.08M | $ -13.24M | $ -22.72M | $ -25.55M | |
| $ -196.00M | $ -76.36M | $ -142.78M | $ -164.92M | $ -123.82M | |
| $ -196.04M | $ -76.42M | $ -143.10M | $ -165.29M | $ -124.09M | |
| Per Share Metrics | |||||
| Basic EPS | $ -17.93 | $ -9.41 | $ -18.79 | $ -30.28 | $ -24.75 |
| Diluted EPS | $ -17.93 | $ -9.41 | $ -18.79 | $ -30.28 | $ -24.75 |
| Weighted Average Shares Outstanding | 10.94M | 8.12M | 7.61M | 5.46M | 5.01M |
| Weighted Average Shares Outstanding (Diluted) | 10.94M | 8.12M | 7.61M | 5.46M | 5.01M |
Currency in USD
